Co-codamol (+Paracetamol)

Quick links to important sections

Co-codamol (+Paracetamol)

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Co-codamol (+Paracetamol)

Co-codamol is a foundational combination analgesic containing two active pharmaceutical ingredients, Codeine and Paracetamol (Acetaminophen), that work together to manage moderate pain and fever. This medicine is defined by its fixed-dose composition, which is clinically recognized for achieving a greater therapeutic benefit than either compound used alone.

Property Description
Active Ingredients Codeine (Opioid), Paracetamol (Acetaminophen)
Form Solid Dosage Forms (Tablets, Capsules, Effervescent Tablets)
Pharmacological Class Combination Analgesic, Opioid Analgesic, Anilide Analgesic
Common Use Relief of pain and fever
Origin Synthetic (both Codeine and Paracetamol)

What Type of Medicine is Co-codamol?

Co-codamol is classified as a combination analgesic, merging a weak opioid with a non-opioid pain reliever, distinguishing it from single-agent formulations. This medicine comprises a weak opioid analgesic (Codeine) and an anilide analgesic/antipyretic (Paracetamol). The Codeine component is specifically identified by the World Health Organization (WHO) as an opioid, which acts on the central nervous system. The combination is considered standard for the second step of the WHO analgesic scale for pain treatment. This positioning indicates the medicine is a recognized pharmacological step in managing discomfort that may not respond sufficiently to non-opioid medications alone, such as pain following minor injuries or certain medical procedures. Its most common physical forms are solid dosage forms such as tablets and capsules, all intended for oral administration.


Composition and Differentiation of Co-codamol

The active ingredients in Co-codamol are the synthetic compounds Codeine (typically as Codeine Phosphate) and Paracetamol (Acetaminophen). Both chemical entities are primarily produced through synthetic processes. The product is definitively a fixed-dose combination, which is the primary differentiating feature from single-ingredient Codeine or Paracetamol products. Brand-name variants that share this formulation include Tylenol with Codeine and Panadeine Forte. This fixed blend is crucial to the medicine's identity and mechanism, as confirmed by regulatory product information.


General Purpose of Co-codamol

The primary function of Co-codamol is to alleviate pain, with an additional antipyretic (fever-reducing) capability contributed by the Paracetamol component. The combination is formulated to offer a dual benefit: Codeine works centrally to dampen the brain's perception of pain, while Paracetamol limits the production of the chemical messengers that signal pain and drive up body temperature. This integrated approach allows the medicine to effectively relieve discomfort and associated feverishness simultaneously.

Regulatory References

  1. Codeine on WHO Essential Medicines List

What side effects are possible with Co-codamol (+Paracetamol)?

The official classification of possible side effects associated with Co-codamol (Codeine and Paracetamol) involves multiple physiological systems, reflecting the action of both active components. Safety statements and frequency classifications are based strictly on regulatory sources.

Serious Adverse Reactions and Key Constraints

The most critical safety characteristics concern the potential for both fatal respiratory depression and acute liver injury (hepatotoxicity). These are the highest-level risks documented in regulatory labeling. The risk of life-threatening respiratory depression from the Codeine component is greatest during the initiation of therapy or following a dosage increase. The risk of acute liver failure from the Paracetamol component is associated with high doses.

Serious reactions also include Addiction, Abuse, and Misuse related to the opioid component, and rare but severe conditions like Stevens-Johnson Syndrome (SJS).

Population-Specific Safety: The medicine is contraindicated in children younger than 12 years of age and is not recommended for post-operative pain management in adolescents under 18 following tonsillectomy and/or adenoidectomy. Use during pregnancy is associated with the risk of Neonatal Opioid Withdrawal Syndrome with prolonged exposure.

Common System-Based Adverse Effects

Adverse effects most frequently observed in clinical use are categorized by the systems they affect:

  • Nervous System: The most common effects are drowsiness, lightheadedness, dizziness, and sedation, reflecting the central activity of Codeine.
  • Gastrointestinal System: Nausea, vomiting, and constipation are frequently reported.
  • Other: The official lists also include shortness of breath, pruritus (itching), rash, and sweating. Safety constraints include limitations for use in individuals with pre-existing conditions such as severe hepatic impairment or significant respiratory depression.

Overdose and Emergency Response

Overdose and When to Seek Help

Immediate medical attention is critical for both adults and children in the event of a suspected overdose, even if no symptoms are immediately apparent. Overdose with Co-codamol presents risks from both active components: paracetamol and codeine.

Signs and Symptoms of Overdose

Symptoms may manifest differently based on the component:

  • Early Paracetamol Toxicity (within 24 hours): Pallor, nausea, vomiting, anorexia, and abdominal pain. The absence of symptoms initially does not exclude the risk of severe, delayed liver damage.
  • Codeine (Opioid) Toxicity: Central nervous system effects such as confusion, somnolence, and coma; respiratory depression (shallow, slow breathing, or apnea); and small (pinpoint) pupils.

Severe Complications

Severe poisoning can progress to life-threatening conditions. The paracetamol component can cause liver damage leading to hepatic failure, hepatic encephalopathy, and death. The codeine component can lead to severe circulatory and respiratory depression.

Emergency Action Required

In case of overdose, seek medical help or contact a Poison Control Center right away. Quick medical intervention is necessary, as the antidote for paracetamol (acetylcysteine) is most effective when administered promptly to prevent or limit liver damage. Treatment for codeine toxicity focuses on supportive care for the respiratory and circulatory systems. The necessity for urgent medical care is the primary step in managing this dual-component overdose.

Therapeutic Uses of Co-codamol (+Paracetamol)

What Co-codamol (+Paracetamol) Treats: Main Uses and Benefits

The primary role of this combination analgesic is to provide supportive symptomatic relief in contexts where symptoms related to physical discomfort are pronounced. The combination is used in situations where additional symptomatic support is needed, such as when symptoms are more noticeable and require stepped-up management. This formulation is used for symptomatic relief of pain and discomfort.


Symptom Relief and Clinical Context

Co-codamol is applied to address pain that is generally characterized by moderate intensity, often including symptoms such as certain toothaches, headaches, musculoskeletal aches, and period pain (dysmenorrhoea). This combination is commonly used across conditions characterized by periods of heightened symptoms that involve both pain and a raised temperature or feverishness, often seen during colds or influenza. The medication helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms.


Therapeutic Benefit

The combination is relevant in contexts marked by increased discomfort or tension. It is applicable within clinical settings that involve acute or disruptive symptom patterns, including pain relief following minor injuries or certain medical procedures. It contributes to easing the overall symptom load and supports patients during difficult episodes by helping to moderate both discomfort and accompanying fever.


Quick Fact: Relief for Moderate Pain Requiring Additional Support


Regulatory References

  1. Paracetamol+Codeine Data Sheet from Medsafe

Eligibility and Restrictions for Use

Eligibility Map: Official Regulatory Information

The eligibility for Co-codamol (Codeine/Paracetamol) is strictly governed by regulatory classifications that define which populations may or must not use the medicine.

Classification Rule Summary (Regulatory Mandate)
Populations Allowed Generally approved for adults who have no documented absolute contraindications or limiting health conditions.
Contraindicated Use is strictly prohibited for children under 12 years of age, individuals known to be CYP2D6 ultra-rapid metabolizers, and women who are breastfeeding. Absolute exclusion also applies to patients with known hypersensitivity to either active ingredient, severe hepatic impairment, or acute respiratory depression.
Restricted/Conditional Use Adolescents (12–18) with compromised breathing or those recovering from tonsillectomy/adenoidectomy are not recommended for use. Older adults and patients with severe renal impairment require greater caution or dose adjustment due to regulatory-mandated restrictions.

Connection to the overall eligibility profile: Official regulatory documents define eligibility by establishing clear contraindications that prohibit use in specific populations due to the risks associated with the Codeine component. The approved population is therefore limited to individuals who are free of these specific age restrictions, metabolic risks, and severe physiological limitations.

What should I know about interactions with other medicines?

Co-codamol’s interaction profile is officially defined by the combined pharmacological effects of Codeine and Paracetamol, leading to specific regulatory constraints for co-administration.

Regulatory documents state that co-administration with Monoamine Oxidase Inhibitors (MAOIs), including moclobemide, is a contraindicated combination due to the enhanced risk of central nervous system (CNS) depression. A major pharmacodynamic interaction is the additive effect with other CNS depressants (such as sedatives, hypnotics, and alcohol), which significantly increases the documented risk of profound sedation and respiratory depression.

Pharmacokinetic interactions involve the Codeine component’s metabolism via the CYP2D6 enzyme. CYP2D6 inhibitors (e.g., fluoxetine, paroxetine) are stated to reduce the conversion of codeine to morphine, potentially decreasing the analgesic effect. Conversely, CYP2D6 inducers officially increase morphine exposure, heightening the risk of opioid toxicity, especially in patients classified as ultra-rapid metabolizers.

A critical restriction is the concurrent use of other Paracetamol-containing products to avoid additive cumulative exposure and the resultant risk of hepatic toxicity. The Paracetamol component also carries a documented interaction with oral anticoagulants like Warfarin, where prolonged high-dose use may increase the International Normalized Ratio (INR). Finally, an absorption-interference constraint is formally documented: Cholestyramine must be administered at least one hour apart to prevent reduced Paracetamol absorption.

Mechanism of Action

Co-codamol's mechanism relies on the complementary pharmacodynamic activities of Codeine and Paracetamol to modulate nociceptive signaling across two distinct central pathways, resulting in integrated physiological modulation.


Central Opioid Receptor Modulation

The Codeine component's action is fundamentally a prodrug mechanism, requiring the liver enzyme CYP2D6 to convert it into the active opioid, Morphine. This active metabolite then acts as an agonist on mu-opioid receptors (MOR) in the brain and spinal cord. Activating these receptors hyperpolarizes pain-sensing neurons, which reduces the release of excitatory neurotransmitters. This mechanism directly interrupts the flow of the nociceptive signal transmission within the central nervous system.


Dual Action on Central Chemical Mediators

Paracetamol's primary effect is centered on the selective, indirect inhibition of Cyclooxygenase (COX) enzymes within the CNS. This action curtails the synthesis of Prostaglandin E2 ( PGE2), a key mediator involved in thermoregulation and nociceptive sensitization. By reducing PGE2 in the hypothalamus, the drug causes the resetting of the body's elevated temperature set-point. Paracetamol also contributes to the modulation of nociceptive input by engaging and potentiating descending inhibitory pathways in the spinal cord, complementing Codeine's direct receptor engagement.

Dosage and Administration Information

How to Use Co-codamol (+Paracetamol)

This section outlines the general principles for the administration and dosing of Co-codamol, based on standard prescribing information, and is intended for short-term use only.


Administration and Dosage Principles

Co-codamol is administered via the oral route across all common dosage forms, which include tablets, capsules, and effervescent preparations. Solid forms are swallowed whole with water, while effervescent tablets must be fully dissolved in a glass of water before consumption. The medicine can be taken with or without food.

The medicine is typically used as needed (PRN) for acute symptoms. Dosing is managed by observing two primary rules: the dose should not be repeated more frequently than every 4 to 6 hours, and the total daily dose should not exceed 8 tablets or the equivalent of 4000 mg of the Paracetamol component in a 24-hour period.

Use Constraints and Adjustments

Co-codamol is intended for short-term treatment only, often with a limit of 3 consecutive days of non-supervised use. If a dose is missed, the next dose should be taken at the next required time, maintaining the minimum interval; a double dose should not be taken.

Population-specific adjustments are recognized: the medicine is contraindicated for use in children under 12 years of age. Dosing for adolescents (12–18 years) is based on age and weight, with a lower maximum dose specified for the 12–15 year group. Further adjustments to the dosing interval are required for patients with renal impairment.

Recent Clinical Evidence

Mechanism of Action Studies

Research has investigated the drug in laboratory studies to understand its action on specific inflammatory pathways. Initial in-vitro and animal studies reported associations between the drug's presence and changes in markers, including Prostaglandin E2 (PGE2) and certain cytokines. Further in-depth laboratory research has focused on the drug's interaction with relevant receptor sites. The analgesic effect of the combination is understood to involve the action of paracetamol and the conversion of codeine to morphine via the CYP2D6 enzyme.


Clinical Trial Findings

Studies have investigated the potential effect on patient outcomes in various randomized controlled trials (RCTs). These trials focused on adults diagnosed with the target condition, often moderate, acute pain.

Efficacy Research

Systematic reviews of single-dose oral paracetamol (acetaminophen) with codeine for postoperative pain have investigated the proportion of patients achieving at least 50% pain relief over a four to six-hour period. For doses of 800 to 1000 mg of paracetamol with 60 mg codeine, studies reported a beneficial change in pain relief compared to placebo. Research evaluated whether the combination was associated with changes in symptoms and quality of life over various treatment lengths.

Combination Therapy

Research evaluated the combination for its potential to address different pain pathways simultaneously. Studies have compared the combination product with paracetamol alone, suggesting that the addition of codeine may be associated with an increase in analgesic effectiveness, although evidence, particularly for low-dose formulations, remains under investigation.


Safety and Tolerability

Study protocols included monitoring of liver enzymes due to potential adverse events related to the paracetamol component. The most frequently reported adverse events in clinical trials included mild gastrointestinal distress, temporary fatigue, and constipation. Current regulatory guidance restricts the use of codeine-containing medicines in certain patient groups, particularly children younger than 12 years of age, due to known risks related to the CYP2D6 metabolism of codeine.

Key Studies & References Analgesic efficacy of paracetamol and its combination with codeine and caffeine in surgical pain: a meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Co-codamol (+Paracetamol) (FAQ)

Q: Why is Co-codamol sometimes only available with a prescription?

Official regulatory agencies classify Co-codamol based on the strength of the codeine component. Higher strengths (such as 15mg or 30mg codeine) are designated as prescription-only medicines (POM) to manage potential risks. This scheduling is put in place to help limit the potential for misuse, dependence, and possible toxicity that can be associated with long-term use.


Q: Does taking Co-codamol affect my ability to drive or operate machinery?

Regulatory documents explicitly warn that the medicine can cause central nervous system effects like drowsiness, dizziness, and sedation. Because of these effects, the ability to drive or operate heavy machinery may be impaired. Regulatory documents state these activities should generally be avoided until the medicine’s effects on an individual are clear.


Q: Can I take Co-codamol if I am already taking ibuprofen?

Official regulatory and product information generally indicates that it is usually acceptable to use Co-codamol alongside ibuprofen. A healthcare professional should be consulted before combining any medicines to check for potential contraindications.


Q: Are there certain herbal supplements that should be avoided while using Co-codamol?

Regulatory sources generally advise that there is limited information to confirm the safety of using complementary or herbal remedies with Co-codamol. Official guidance emphasizes the need to inform a doctor or pharmacist about all supplements being taken.


Q: How long does the pain relief from Co-codamol typically last?

Official information indicates that the pain-relieving effects of Co-codamol typically last for approximately four to six hours. This duration is consistent with the required time interval before a subsequent dose may be taken, as stated in the product information.


Q: How quickly should I expect to feel the effect after taking a dose?

The medicine is generally expected to start working within about half an hour of taking a dose. The maximum level of pain relief from the codeine and paracetamol combination is often reported to be reached around two hours after consumption.


Q: Is it possible to become tolerant to the effects of Co-codamol over time?

Yes, regulatory documents mention that tolerance to the effects of the codeine component can develop with chronic use. This means that over time, the medicine may become less effective at the same dose.


Q: Why do some tablets contain different strengths of the codeine component?

Co-codamol is a combination medicine where the amount of paracetamol is always 500mg, but the codeine amount varies (e.g., 8mg, 15mg, or 30mg). The specific codeine strength determines the overall analgesic potency and, crucially, whether the product is available over-the-counter or requires a prescription.


Q: Can I take Co-codamol for a headache?

Co-codamol is indicated for the general relief of pain. Official regulatory documents do not usually list specific types of pain like headache. Its approved use is restricted to the management of acute moderate pain when non-opioid analgesics alone are considered insufficient.


Q: Why do certain countries have restrictions on buying Co-codamol?

Restrictions on purchasing the medicine, such as requiring a prescription for all strengths, are implemented by regulatory bodies (like the TGA in Australia). This is based on evidence of harm from dependence, misuse, and toxicity associated with the easy availability of low-strength codeine products.


Q: Does Co-codamol affect blood pressure?

The opioid component (codeine) can potentially cause a drop in blood pressure, known as hypotension. Official safety labels list this as a possible adverse reaction, particularly when high doses are used or in patients who are more susceptible.


Q: Do studies suggest Co-codamol is less effective for certain types of chronic pain?

Co-codamol is officially labeled for the short-term treatment of acute moderate pain. Regulatory documents warn that using it for prolonged or chronic periods may lead to the development of tolerance and dependence, which limits its use in chronic pain management.


Q: What is the general guidance on stopping Co-codamol use?

Regulatory guidance states that if the medicine has been used regularly for an extended period, abrupt discontinuation is not recommended. A healthcare professional should be consulted to manage the discontinuation process through a gradual dose reduction (tapering), which is intended to minimize the risk of withdrawal symptoms.


Q: Can Co-codamol be used for pain after dental work?

Co-codamol is indicated for the relief of acute moderate pain. While dental work frequently causes acute pain, regulatory labels list the general indication rather than specific procedures, placing it within the scope of acute pain management.


Q: What should I do if the medicine does not seem to be relieving the pain?

If the pain is not adequately controlled after taking the medicine for the maximum period recommended for non-prescribed use (often 3 days), official guidance states that a healthcare professional should be consulted for further evaluation.


Q: What are the reported effects of long-term use of Co-codamol?

The long-term use of Co-codamol is generally not recommended by regulatory bodies. Prolonged use can lead to the development of drug tolerance and physical dependence or addiction, even when taken at therapeutic doses.


Q: Does Co-codamol appear on standard drug screening tests?

Yes, the codeine component is an opiate and is typically detectable on standard urine drug screening tests for opioids. Codeine is metabolized in the body into substances like morphine, which are also often detectable targets in these screening processes.


Q: What is the meaning of the number (like 8/500) that is often part of the name?

The two numbers in the product name indicate the strength of the two active components in milligrams per dose. The first number refers to the amount of Codeine (e.g., 8mg), and the second number refers to the amount of Paracetamol (e.g., 500mg).

How should Co-codamol (+Paracetamol) be stored and disposed of?

Storage and Disposal Requirements

Co-codamol must be stored under specific conditions as mandated by regulatory labeling. The medicine should be kept at controlled room temperature, generally below 25 C, and must be protected from light and moisture. It is required to be stored in its original container with the lid tightly closed and must not be frozen.

Due to the codeine component, the product must be stored securely, out of the sight and reach of children and others. Unused or expired medication should be disposed of via an official drug take-back program. As instructed by official guidance, the medicine must not be disposed of via wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Co-codamol (+Paracetamol) found in:

A-Z Index: